Issue Date: November 2, 2009
Astellas Signs Up Medivation Drug
Astellas Pharma and Medivation have signed a deal to develop and co-commercialize MDV3100, a Medivation drug currently in Phase III trials for the treatment of prostate cancer. Under the agreement, San Francisco-based Medivation will receive an up-front cash payment of $100 million and milestone payments of up to $335 million. “We believe that MDV3100 has the unique potential to establish a new treatment approach for prostrate cancer,” Astellas CEO Masafumi Nogimori says.
- Chemical & Engineering News
- ISSN 0009-2347
- Copyright © American Chemical Society